Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Nyse  >  Allergan plc    AGN   IE00BY9D5467

My previous session
Most popular
News SummaryMost relevantAll newsOfficial PublicationsSector newsTweets

Allergan : Trump to keep Obama rule curbing corporate tax inversion deals

share with twitter share with LinkedIn share with facebook
share via e-mail
10/05/2017 | 04:55pm CEST
U.S. President Donald Trump departs Washington aboard Air Force One

(This October 4 story fixes comment by Organization for International Investment as referring to historically foreign-based companies in paragraph 13.)

President Donald Trump ordered a review almost six months ago of tax rules from the final months of the Obama administration, including ones to discourage companies from redomiciling abroad for tax reasons.

"Treasury plans to retain the distribution requirements under Section 385 pending enactment of tax reform," the department said in a statement, adding "these regulations are necessary to safeguard against earnings stripping."

It also said it planned to revoke and streamline some related documentation rules.

A 2011-2015 wave of inversion deals prompted Treasury to take a series of actions that culminated in an April 2016 rule release and the collapse of a $160-billion deal between U.S. drugmaker Pfizer Inc (>> Pfizer) and Ireland’s Allergan Plc (>> Allergan plc), which would have been the largest inversion ever.

Tax inversions occur when a U.S. company is acquired by a smaller foreign business from a low-tax country and adopts its domicile to reduce the combined firm’s overall U.S. tax burden.

The Section 385 rule was part of Obama's anti-inversion effort and was finalized a year ago. It was meant to combat a corporate tax-reduction technique known as earnings stripping.

Earnings stripping occurs when the U.S. subsidiary of a newly inverted company loads up on debt and avoids taxes on its domestic profits by sending them overseas to the foreign parent in the form of tax-deductible interest payments.

The Obama rule reclassified some forms of debt as equity, changing tax-exempt interest payments into taxable dividends and making earnings stripping strategies more difficult to pursue.

The Organization for International Investment (OFII), a Washington lobbying group for foreign-based companies with U.S. operations, praised the documentation portion of Treasury's latest move and criticized the retention of the rest of the Section 385 rule.

"Unfortunately, in perpetuating an unsubstantiated premise of the Obama administration, Treasury has decided to keep part of these discriminatory regulations," the group said.

Companies with historic foreign headquarters that have expanded into the United States, OFII said in a statement, "are not overleveraged, their debt levels have remained largely flat and their interest expense has declined while their investments into America’s economy have grown."

The Treasury Department said it expected a Republican proposal to overhaul the tax code would eliminate the need for anti-inversion rules. The proposal would sharply cut the corporate tax rate and end taxation of multinationals' foreign profits.

(Writing by Kevin Drawbaugh; Editing by Susan Thomas)

Stocks treated in this article : Allergan plc, Pfizer
Stocks mentioned in the article
ChangeLast1st jan.
ALLERGAN PLC 0.97% 186.07 Delayed Quote.13.75%
PFIZER 1.16% 43.51 Delayed Quote.18.75%
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on ALLERGAN PLC
09/18ALLERGAN : to Acquire Bonti Adding New Neurotoxin Programs to Medical Aesthetics..
09/17ALLERGAN : Announces Results of Higher Dose BOTOX Cosmetic (onabotulinumtoxinA) ..
09/17CEL SCI : Botox Effect Lasts Longer At Higher Doses, TEVA Gets FDA Nod, KNSA On ..
09/15ALLERGAN : to Acquire Bonti Adding New Neurotoxin Programs to Medical Aesthetics..
09/14ALLERGAN : Announces Results of Higher Dose BOTOX® Cosmetic (onabotulinumtoxinA)..
09/14ALLERGAN : Highlights Key Growth Drivers for Medical Aesthetics
09/14Allergan says revenue from aesthetics unit may double by 2025
09/14ALLERGAN : Unveils Spotlyte, a First-In-Category Digital Hub Designed To Educate..
09/14ALLERGAN : to Acquire Bonti Adding New Neurotoxin Programs to Medical Aesthetics..
09/13THE MOST EXCITING ADVANCE IN SKINCAR : Introducing the SkinMedica® LUMIVIVE&trad..
More news
News from SeekingAlpha
09/18Allergan Snaps Up Early Stage Startup, Goes Back To Its Aesthetic Roots 
09/18YOUR DAILY PHARMA SCOOP : Alnylam Regains, Karyopharm Positive, Teva Approved 
09/18Senate passes opioid crisis bill 
09/17House nixes drug prices in TV ads 
09/14Allergan's Botox shows treatment benefit at higher doses 
Financials ($)
Sales 2018 15 533 M
EBIT 2018 7 411 M
Net income 2018 -1 106 M
Debt 2018 23 063 M
Yield 2018 1,49%
P/E ratio 2018 -
P/E ratio 2019
EV / Sales 2018 5,55x
EV / Sales 2019 5,32x
Capitalization 63 160 M
Duration : Period :
Allergan plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ALLERGAN PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 212 $
Spread / Average Target 14%
EPS Revisions
Brenton L. Saunders Chairman, President & Chief Executive Officer
Wayne R. Swanton Executive Vice President-Global Operations
Matthew M. Walsh Chief Financial Officer & Executive Vice President
C. David Nicholson Chief Research & Development Officer
Charles Hugh-Jones Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
ALLERGAN PLC13.75%62 556
JOHNSON & JOHNSON0.59%375 479
PFIZER18.75%252 129
NOVARTIS-1.14%215 800
ROCHE HOLDING LTD.-4.00%212 015
MERCK AND COMPANY25.15%187 284